Delafloxacin

Addressing the pain point of insufficient activity of existing fluoroquinolone drugs in the clinical treatment of multidrug-resistant Gram-positive bacterial infections, delafloxacin, as a new generation of fluoroquinolone antibacterial agent, demonstrates unique clinical advantages. Its mechanism of action is to inhibit bacterial DNA gyrase and topoisomerase IV, and the dual-target action effectively reduces the risk of drug resistance. It has strong antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and multidrug-resistant Streptococcus pneumoniae, among others, while retaining its effect against Gram-negative bacteria. It is clinically mainly used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) in adults, providing a new medication option for high-risk populations with drug-resistant bacterial infections.

At present, the global delafloxacin market is still in the stage of rapid expansion. In 2023, the global market size was approximately USD 120 million, with a compound annual growth rate of around 18%. The core growth drivers come from the continuous rise in the incidence of global drug-resistant bacterial infections and the increasing clinical demand for new fluoroquinolone drugs. The domestic market is still in the introduction period. As the patent of the original research drug has just expired, only 2 domestic enterprises have submitted marketing applications for generic drugs, so the market competition pattern is relatively loose. With the subsequent approval of generic drugs and the advancement of medical insurance coverage, it is expected that the domestic market size will exceed RMB 200 million in the next 3 years.

The original research enterprise of delafloxacin is Melinta Therapeutics, and the original research brand name is Baxdela. The expiration date of its core compound patent in the United States is 2026, and the expiration date of the compound patent in China is 2024. The main dosage forms approved for the original research drug include tablets and injections, with the tablet specification being 450 mg and the injection specification being 300 mg. The original research preparation has been included in the FDA Reference Listed Drug Catalog. At present, the original research preparation has not been imported into China. 3 domestic enterprises have submitted registration applications for delafloxacin API, among which 1 has obtained the A-status registration number, and the oral preparations of delafloxacin from another 2 enterprises have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information.)

CATO can provide a full set of impurity reference standards for delafloxacin API, which fully meets the impurity research requirements in the process of generic drug consistency evaluation and API registration. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products comply with the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, which can effectively shorten the R&D cycle and reduce research risks.